News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
702,862 Results
Type
Article (40147)
Company Profile (271)
Press Release (662444)
Multimedia
Podcasts (55)
Webinars (12)
Section
Business (205168)
Career Advice (2021)
Deals (35541)
Drug Delivery (97)
Drug Development (81282)
Employer Resources (172)
FDA (16229)
Job Trends (14922)
News (346610)
Policy (32665)
Tag
Academia (2572)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49815)
ALS (94)
Alzheimer's disease (1389)
Antibody-drug conjugate (ADC) (135)
Approvals (16224)
Artificial intelligence (262)
Autoimmune disease (23)
Automation (16)
Bankruptcy (363)
Best Places to Work (11658)
BIOSECURE Act (20)
Biosimilars (107)
Biotechnology (190)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (291)
Cancer (2314)
Cardiovascular disease (179)
Career advice (1689)
Career pathing (30)
CAR-T (156)
Cell therapy (439)
Cervical cancer (20)
Clinical research (66226)
Collaboration (863)
Company closure (2)
Compensation (557)
Complete response letters (19)
COVID-19 (2606)
CRISPR (42)
C-suite (252)
Cystic fibrosis (101)
Data (2299)
Decentralized trials (2)
Denatured (21)
Depression (44)
Diabetes (276)
Diagnostics (6399)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (104)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (87121)
Editorial (40)
Employer branding (21)
Employer resources (146)
Events (113136)
Executive appointments (744)
FDA (17594)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (770)
Gene editing (111)
Generative AI (19)
Gene therapy (309)
GLP-1 (720)
Government (4441)
Grass and pollen (4)
Guidances (150)
Healthcare (18840)
Huntington's disease (25)
IgA nephropathy (27)
Immunology and inflammation (129)
Indications (29)
Infectious disease (2752)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (53)
Intellectual property (97)
Interviews (312)
IPO (16555)
IRA (42)
Job creations (3670)
Job search strategy (1434)
Kidney cancer (10)
Labor market (43)
Layoffs (482)
Leadership (17)
Legal (7947)
Liver cancer (76)
Lung cancer (324)
Lymphoma (156)
Machine learning (9)
Management (58)
Manufacturing (324)
MASH (73)
Medical device (13393)
Medtech (13398)
Mergers & acquisitions (19553)
Metabolic disorders (704)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (96)
Neuropsychiatric disorders (27)
Neuroscience (1943)
NextGen: Class of 2025 (6549)
Non-profit (4492)
Now hiring (40)
Obesity (371)
Opinion (208)
Ovarian cancer (80)
Pain (92)
Pancreatic cancer (89)
Parkinson's disease (151)
Partnered (21)
Patents (241)
Patient recruitment (115)
Peanut (46)
People (57687)
Pharmaceutical (67)
Pharmacy benefit managers (19)
Phase I (20643)
Phase II (29176)
Phase III (21714)
Pipeline (1344)
Policy (150)
Postmarket research (2571)
Preclinical (8791)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (383)
Real estate (5954)
Recruiting (65)
Regulatory (22403)
Reports (47)
Research institute (2327)
Resumes & cover letters (350)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (134)
Series B (87)
Service/supplier (13)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (148)
Sponsored (29)
Startups (3634)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (48)
The Weekly (32)
Vaccines (700)
Venture capitalists (44)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (27)
Last 7 days (936)
Last 30 days (3010)
Last 365 days (32502)
2025 (11717)
2024 (35339)
2023 (40182)
2022 (51290)
2021 (55836)
2020 (54160)
2019 (46645)
2018 (35128)
2017 (32225)
2016 (31632)
2015 (37716)
2014 (31458)
2013 (26511)
2012 (28777)
2011 (29436)
2010 (27531)
Location
Africa (721)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (38097)
Australia (6238)
California (6393)
Canada (2060)
China (533)
Colorado (273)
Connecticut (278)
Delaware (156)
Europe (82004)
Florida (946)
Georgia (212)
Idaho (58)
Illinois (548)
India (26)
Indiana (320)
Iowa (11)
Japan (171)
Kansas (107)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (919)
Massachusetts (4745)
Michigan (223)
Minnesota (401)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (64)
New Jersey (1785)
New Mexico (28)
New York (1795)
North Carolina (986)
North Dakota (8)
Northern California (2809)
Ohio (210)
Oklahoma (14)
Oregon (35)
Pennsylvania (1419)
Puerto Rico (13)
Rhode Island (33)
South America (1100)
South Carolina (25)
South Dakota (1)
Southern California (2409)
Tennessee (105)
Texas (950)
United States (23930)
Utah (188)
Virginia (152)
Washington D.C. (65)
Washington State (565)
West Virginia (3)
Wisconsin (56)
702,862 Results for "ucb biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eye Second Phase III
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB are planning a second late-stage trial by the end of the year to support a drug application.
November 19, 2024
·
3 min read
·
Tristan Manalac
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
UCB Offloads Neurology, Allergy Portfolio in China for $680M
Belgium-based biopharma UCB is selling its Chinese neurology and allergy business to Singapore asset management firm CBC Group and Abu Dhabi investment company Mubadala.
August 26, 2024
·
1 min read
·
Annalee Armstrong
Press Releases
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
April 3, 2025
·
34 min read
Press Releases
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
May 8, 2025
·
16 min read
Press Releases
Parse Biosciences Partners with Japanese Distributor, SCRUM Inc.
April 2, 2025
·
2 min read
Press Releases
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
May 8, 2025
·
6 min read
Press Releases
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
·
14 min read
Press Releases
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
April 23, 2025
·
4 min read
Press Releases
Xenetic Biosciences, Inc. Releases Virtual Investor “What This Means” Segment
April 10, 2025
·
5 min read
1 of 70,287
Next
